Microglial knockdown does not affect acute withdrawal but delays analgesic tolerance from oxycodone in male and female C57BL/6J mice
Advances in Drug and Alcohol Research · 2022
DOI: 10.3389/adar.2022.10848 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Drug and Alcohol Research, 2022. Verfasst von Omar El Jordi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Indiana University, Indianapolis, IN, United States. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, NCATS NIH HHS, Indiana University Health.
Abstract (Originalsprache)
Opioid Use Disorder (OUD) affects approximately 8%–12% of the population. In dependent individuals, abrupt cessation of opioid taking results in adverse withdrawal symptoms that reinforce drug taking behavior. Considerable unmet clinical need exists for new pharmacotherapies to treat opioid withdrawal as well as improve long-term abstinence. The neuroimmune system has received much scientific attention in recent years as a potential therapeutic target to combat various neurodegenerative and psychiatric disorders including addiction. However, the specific contribution of microglia has not been investigated in oxycodone dependence. Chronic daily treatment with the CSF1R inhibitor Pexidartinib (PLX3397) was administered to knockdown microglia expression and evaluate consequences on analgesia and on naloxone induced withdrawal from oxycodone. In vivo results indicated that an approximately 40% reduction in brain IBA1 staining was achieved in the PLX treatment group, which was associated with a delay in the development of analgesic tolerance to oxycodone and maintained antinociceptive efficacy. Acute withdrawal behavioral symptoms, brain astrocyte expression, and levels of many neuroinflammatory markers were not affected by PLX treatment. KC/GRO (also known as CXCL1) was significantly enhanced in the somatosensory cortex in oxycodone‐treated mice receiving PLX. Microglial knock-down did not affect the expression of naloxoneinduced opioid withdrawal but affected antinociceptive responsivity. The consequences of increased KC/GRO expression within the somatosensory cortex due to microglial reduction during opioid dependence are unclear but may be important for neural pathways mediating opioid‐induced analgesia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Indiana University, Indianapolis, IN, United States.
- Department of Radiology and Imaging Sciences, Indiana University, Indianapolis, IN, United States.
Förderung
- NIAAA NIH HHS
- NCATS NIH HHS
- Indiana University Health
- Indiana Clinical and Translational Sciences Institute
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
El Jordi, O., Fischer, K. D., Meyer, T. B., Atwood, B. K., Oblak, A. L., Pan, R. W., & McKinzie, D. L. (2022). Microglial knockdown does not affect acute withdrawal but delays analgesic tolerance from oxycodone in male and female C57BL/6J mice. Advances in Drug and Alcohol Research. https://doi.org/10.3389/adar.2022.10848
Vancouver
El Jordi O, Fischer KD, Meyer TB, Atwood BK, Oblak AL, Pan RW, et al. Microglial knockdown does not affect acute withdrawal but delays analgesic tolerance from oxycodone in male and female C57BL/6J mice. Advances in Drug and Alcohol Research. 2022. doi:10.3389/adar.2022.10848
BibTeX
@article{ElJordi2022,
author = {El Jordi, Omar and Fischer, Kathryn D and Meyer, Timothy B and Atwood, Brady K and Oblak, Adrian L and Pan, Raymond W and McKinzie, David L},
title = {Microglial knockdown does not affect acute withdrawal but delays analgesic tolerance from oxycodone in male and female C57BL/6J mice},
journal = {Advances in Drug and Alcohol Research},
year = {2022},
doi = {10.3389/adar.2022.10848}
}
EUVIMED